This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Browse
Bempedoic acid
Liver-targeted ACL inhibitor → ~20% LDL-C reduction without statin myalgia.
Aliases (3)
Nexletol · Nilemdo · ETC-1002
TYPICAL DOSE
—
ROUTE
—
CYCLE
—
STORAGE
—
Overview
What is Bempedoic acid?
Liver-targeted ACL inhibitor → ~20% LDL-C reduction without statin myalgia. Standard-of-care for statin intolerance post-CLEAR Outcomes (2023). WATCH-LIST — relevant if lipid risk ever appears.
What to Expect
- Week 1Tolerability and dose-response.
- Week 2-4Early effect window.
- Week 4-8Peak benefit assessment.
- Week 8+Cycle decision point.
Was this helpful?
Your feedback shapes what we research deeper.
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
Loading…
✎
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.
Discussion — click to load ▸
Loading…
Continue: Extended research →
Our verdict, decision matrix, deep dives, controversies, sources